drugset / Trial / NCT00138281

Influenza Immunity Against Pandemic Respiratory Virus

NCT00138281

RandomizedParallel-groupOpen-labelPrevention

Summary

Sixty adults, ages 18-49, will be randomly assigned to receive either FluMist or Fluzone. Some of the subjects will have participated in previous studies for these 2 vaccines. The study will last 4 months with subject participation being 28 days. The purpose of this study is to measure immune response to the vaccinations.

Timeline

Start
Primary completion
2005-11
Completion
2006-01

Drugs

EvaluationDrugModalityDoseRoute
Subject FluMist Vaccine Intranasal
Subject Influenza Virus Vaccine Vaccine Intramuscular

Indications